Dr. Heymach on the Significance of Nivolumab for Lung Cancer

John V. Heymach, MD, PhD
Published: Friday, Jun 02, 2017



John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.

The long-term follow-up for nivolumab is important for the field, states Heymach. Overall, patients in the CheckMate-026 trial saw an improvement in survival of a few months.

The long-term data informs researchers that there are some patients that are still benefitting from the treatment years later, explains Heymach.



John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.

The long-term follow-up for nivolumab is important for the field, states Heymach. Overall, patients in the CheckMate-026 trial saw an improvement in survival of a few months.

The long-term data informs researchers that there are some patients that are still benefitting from the treatment years later, explains Heymach.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x